Valuation: Sumitomo Pharma Co., Ltd.

Capitalization 778B 4.91B 4.21B 3.85B 3.67B 6.73B 470B 6.8B 45.57B 17.81B 224B 18.44B 18.05B P/E ratio 2026
7.72x
P/E ratio 2027 * 8.63x
Enterprise value 931B 5.88B 5.04B 4.6B 4.39B 8.06B 563B 8.14B 54.57B 21.33B 268B 22.08B 21.61B EV / Sales 2026
1.82x
EV / Sales 2027 * 1.45x
Free-Float
57.61%
Yield 2026 *
-
Yield 2027 * 0.57%

Last Transcript: Sumitomo Pharma Co., Ltd.

1 day+5.09%
1 week+0.26%
Current month+0.84%
1 month-12.02%
3 months-29.81%
6 months-26.59%
Current year-25.19%
1 week 1,481
Extreme 1481
1,803.5
1 month 1,481
Extreme 1481
2,227.5
Current year 1,481
Extreme 1481
3,288
1 year 744
Extreme 744
3,288
3 years 279
Extreme 279
3,288
5 years 279
Extreme 279
3,288
10 years 279
Extreme 279
4,135
Manager TitleAgeSince
Chief Executive Officer 65 24/06/2024
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 31/03/2022
Director TitleAgeSince
Director/Board Member 64 24/06/2025
Director/Board Member 65 31/05/2016
Director/Board Member 62 31/05/2018
Change 5d. change 1-year change 3-years change Capi.($)
+5.09%+0.26%+99.77%+119.22% 4.69B
-0.89%+1.99%+34.94%+131.73% 906B
+0.16%+2.75%+55.48%+43.55% 555B
+1.09%+2.80%+12.11%+43.23% 368B
-0.94%-2.05%+21.74%+10.73% 326B
-0.19%+1.28%+34.97%+14.40% 289B
+0.78%+1.00%+29.63%+26.23% 285B
-0.04%-0.13%+48.00%-3.18% 280B
+0.91%+2.12%-31.78%-49.10% 208B
-0.07%+1.55%+24.32%+44.34% 182B
Average +0.58%+0.52%+32.92%+38.11% 340.31B
Weighted average by Cap. +0.03%+1.24%+30.63%+50.55%

Financials

2026 2027 *
Net sales 441B 2.78B 2.38B 2.18B 2.08B 3.82B 266B 3.85B 25.83B 10.09B 127B 10.45B 10.23B 548B 3.46B 2.97B 2.71B 2.58B 4.75B 331B 4.79B 32.12B 12.55B 158B 13B 12.72B
Net income 99.3B 627M 537M 491M 468M 860M 60.03B 868M 5.82B 2.27B 28.6B 2.35B 2.3B 87.02B 549M 471M 430M 410M 753M 52.61B 761M 5.1B 1.99B 25.07B 2.06B 2.02B
Net Debt 153B 969M 830M 759M 723M 1.33B 92.78B 1.34B 8.99B 3.51B 44.21B 3.64B 3.56B 15.73B 99.27M 85.08M 77.75M 74.12M 136M 9.51B 138M 921M 360M 4.53B 373M 365M
Logo Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co Ltd, formerly Sumitomo Dainippon Pharma Co Ltd, is a Japan-based pharmaceutical company. The Company operates its business through four segments. The Japan segment is engaged in the manufacture, purchase, and sale of ethical drugs. The North American segment is engaged in the manufacture, purchase, and sale of ethical drugs and conducts research and development in the areas of oncology, urology, respiratory disease, and regenerative cell medicine. The China segment is engaged in the manufacture (small packaged products) and sale of ethical pharmaceuticals. The Overseas Others segment is engaged in the manufacture and sale of ethical pharmaceuticals in Europe. The segment also purchase and sell ethical pharmaceuticals in Southeast Asia and Taiwan, as well as provide information and collection activities for the Company's products. Other business includes manufacturing, purchasing, and sales of food ingredients, food additives and chemical product materials.
Employees
3,832
Date Price Change Volume
14/05/26 1,734.00 ¥ +5.09% 14,480,100
13/05/26 1,650.00 ¥ +2.52% 19,041,600
12/05/26 1,609.50 ¥ -5.85% 8,441,200
11/05/26 1,709.50 ¥ +5.98% 9,822,600
08/05/26 1,613.00 ¥ -2.66% 13,644,800
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
1,734.00JPY
Average target price
2,121.43JPY
Spread / Average Target
+22.34%

Quarterly revenue - Rate of surprise